Will Nanotechnology Bring New Hope for Gene Delivery?

Wong, Joanna; Mohseni, Rashin; Hamidieh, Amir Ali; MacLaren, Robert E.; Habib, Nagy; Seifalian, Alexander M.

doi:10.1016/j.tibtech.2016.12.009

Cited by 101 publications

(53 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, numerous types of delivery systems have been established to effectively defend decoy ODNs against the destructive function of nucleases and to enhance their permeation in to the cell and cytoplasm with least possible degradation amount (Wang et al, 2015). Several unique properties of nanocarriers including biocompatibility, biodegradability, physical stability in blood and other body fluids, lack of immunogenicity and induction of sustained and prolonged gene expression have made them to be considered as ideal gene vectors (Wong et al, 2017). Nanotechnology-based systems for decoy ODN delivery generally consists of biocompatible systems including nanoparticles and nanospheres, which can be made from both natural and synthetic materials, cationic solid lipid nanoparticles and nano-sized cationic liposomes which have been successfully applied for improving the pharmacokinetic profile of decoys (Panyam & Labhasetwar, 2003;Morachis et al, 2012).…”

Section: Why Nanomaterials Based Delivery For Decoy Oligonucleotides?mentioning

confidence: 99%

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

2017

View full text Add to dashboard Cite

As a prototypical pro-inflammatory transcription factor, constitutive activation of NF-κB signaling pathway has been reported in several chronic inflammatory disorders including inflammatory bowel disease, cystic fibrosis, rheumatoid arthritis and cancer. Application of decoy oligodeoxynucleotides (ODNs) against NF-κB, as an effective molecular therapy approach, has brought about several promising outcomes in treatment of chronic inflammatory disorders. However, systematic administration of these genetic constructs is mostly hampered due to their instability, rapid degradation by nucleases and poor cellular uptake. Both chemical modification and application of delivery systems have shown to effectively overcome some of these limitations. Among different administered delivery systems, nanomaterials have gained much attention for delivering NF-κB decoy ODNs owing to their high loading capacity, targeted delivery and ease of synthesis. In this review, we highlight some of the most recently developed nanomaterial-based delivery systems for overcoming limitations associated with clinical application of these genetic constructs.

show abstract

Section: Why Nanomaterials Based Delivery For Decoy Oligonucleotides?mentioning

confidence: 99%

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

2017

View full text Add to dashboard Cite

show abstract

“…Polymeric nanoparticles (PNs) are molecules usually organized with tunable size into a dense structure with entangling biodegradable polymers presenting thermodynamic stability in an aqueous solvent (72)(73)(74)(75). Recently, FDA approved three PNs, namely, polylactic acid (PLA), poly (lactic-co-glycolic acid) 43 (PLGA), and polycaprolactone (PCL).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

“…Gene therapy is a potentially promising strategy for the treatment of renal fibrosis in vivo because it can target molecules that were previously difficult to set as therapeutic targets using small molecules or antibodies. The development of nano-sized carriers including viral vectors and non-viral vectors has been shown to enhance the delivery and treatment effects of gene therapy for various diseases, including renal fibrosis in vivo [11–14]. …”

Section: Introductionmentioning

confidence: 99%

Nano-sized carriers in gene therapy for renal fibrosisin vivo

Miyazawa

Hirai

Ookawara

et al. 2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Renal fibrosis is the final common pathway leading to end-stage renal failure regardless of underlying initial nephropathies. No specific therapy has been established for renal fibrosis. Gene therapy is a promising strategy for the treatment of renal fibrosis. Nano-sized carriers including viral vectors and non-viral vectors have been shown to enhance the delivery and treatment effects of gene therapy for renal fibrosis in vivo. This review focuses on the mechanisms of renal fibrosis and the in vivo technologies and methodologies of nano-sized carriers in gene therapy for renal fibrosis. RESPONSIBLE EDITOR Alexander Seifalian Director of Nanotechnology & Regenerative Medicine Ltd., The London BioScience Innovation Centre, London, UNITED KINGDOM

show abstract

Will Nanotechnology Bring New Hope for Gene Delivery?

Cited by 101 publications

References 89 publications

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Nano-sized carriers in gene therapy for renal fibrosisin vivo

Contact Info

Product

Resources

About